Following the approval of olaparib in breast cancer, the FDA also approved another PARP inhibitor, talazoparib for patients with germline BRCA-mutated, HER2‐negative locally advanced or metastatic breast cancer in the same year [47]. This evidence concerns the gene ERBB2 and breast carcinoma.